JSR Life Sciences Corporation Begins Beta Testing ExoCap™ for Exosome Elution and Purification

Sunnyvale, CA – Feb. 5, 2013 – JSR Life Sciences Corporation, announced today that ExoCap™, a complete kit based on the company’s Magnosphere™ magnetic particles and proprietary antibodies for the purification and elution of exosomes from serum, plasma, urine, and cell culture media, has begun beta testing. Exosome isolation is considered a highly promising technology for the non-invasive and early detection of cancer and infectious diseases. Exosomes are released from most cell types in the body including those that make up tissues and fluids. Because exosomes contain proteins and RNA, it is believed that isolating them from blood or urine samples can offer a window into the cells that compose other parts of the body such as organs and tissues.

“Exosome elution and purification has the potential to change how we diagnose some of the world’s worst diseases by helping us to identify them much earlier,” said Tim Lowery, Vice President of JSR Micro, JSR Life Sciences’ US distributor.

“Because the exosomes in blood or urine contain the same information as those in the kidneys, heart or lungs, we may be able to eliminate invasive biopsies and be able to detect these diseases much earlier in the diagnostic process.”

JSR Life Sciences’ magnetic bead-based ExoCap enables up to 77 percent faster and easier processing than ultracentrifuge and cleaner purification than precipitation methods. The solution also offers low nonspecific binding and the ability to elute intact exosomes. The ExoCap kit includes a stabilizer buffer, conjugated Magnosphere magnetic beads, a wash buffer and multiple elution buffers for a variety of downstream assays. ExoCap is being beta tested at major research facilities in the US.